A modified herpes simplex virus type 1 (HSV-1), engineered to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF), was approved by FDA in 2015 for treatment of advanced melanoma (6). The gene discussed is CSF2; the disease is melanoma.